Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat and AGS-004 in Persistent HIV-1 Infection
NCT02707900Phase 1Terminated
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Mar 2016
- Primary completion
- Jul 2018
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rocapuldencel-T in human immunodeficiency virus type 1 infection (HIV-1), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Change in the frequency of HIV infection per million resting CD4+T cells at Week 72 and Occurrence of at least one >= Grade 3 adverse event at Week 96. Started Mar 2016; status: terminated.
02
Drugs
rocapuldencel-T
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02707900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707900.